{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=23&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Denver",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 7451,
    "total_pages": 746,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=24&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=22&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T07:01:50.823Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02466516",
      "title": "Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "SIM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 72,
      "start_date": "2015-06-08",
      "completion_date": "2016-10-11",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 26,
      "location_summary": "Palo Alto, California • San Diego, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02466516"
    },
    {
      "nct_id": "NCT04173507",
      "title": "Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Non-Squamous Non-Small Cell Carcinoma",
        "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 47,
      "start_date": "2020-02-14",
      "completion_date": "2024-05-01",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 325,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173507"
    },
    {
      "nct_id": "NCT00510471",
      "title": "Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genitope Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2007-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-03-18",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00510471"
    },
    {
      "nct_id": "NCT00127283",
      "title": "Recombinant Factor VIIa in Acute Intracerebral Haemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Intracerebral Haemorrhage"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 829,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127283"
    },
    {
      "nct_id": "NCT02758431",
      "title": "Cardiovascular Outcomes of Low Testosterone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Acyline",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        },
        {
          "name": "Testosterone Gel",
          "type": "DRUG"
        },
        {
          "name": "Arimidex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 232,
      "start_date": "2016-07-01",
      "completion_date": "2023-01-04",
      "has_results": false,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02758431"
    },
    {
      "nct_id": "NCT00401193",
      "title": "Efficacy and Safety of XP12B in Women With Menorrhagia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menorrhagia",
        "Heavy Menstrual Bleeding"
      ],
      "interventions": [
        {
          "name": "Tranexamic acid tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 304,
      "start_date": "2006-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2015-05-13",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401193"
    },
    {
      "nct_id": "NCT02514447",
      "title": "Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2015-10-05",
      "completion_date": "2021-10-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 35,
      "location_summary": "Hot Springs, Arkansas • Rogers, Arkansas • Corona, California + 28 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02514447"
    },
    {
      "nct_id": "NCT02403843",
      "title": "RNS® System Epilepsy Post-Approval Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "RNS System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NeuroPace",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 345,
      "start_date": "2015-06",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Irvine, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02403843"
    },
    {
      "nct_id": "NCT00003635",
      "title": "506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "nelarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-01",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2013-07-18",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003635"
    },
    {
      "nct_id": "NCT01088243",
      "title": "Targeting Oxidative Stress in Chronic Beryllium Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Beryllium Disease"
      ],
      "interventions": [
        {
          "name": "Mesalamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-03",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-10-12",
      "last_synced_at": "2026-11-02T07:01:50.823Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088243"
    }
  ]
}